Stay updated on Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedLocations section updated to include new site entries across the US and international regions; earlier location groupings were removed.SummaryDifference2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedAdded a note that PubMed publications are auto-filled and may not be about the study, updated the revision to v3.3.2, and removed the older PubMed note and revision v3.2.0—To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check50 days agoChange DetectedThe page no longer displays a government funding lapse disclaimer; the study details are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedNo substantive content changes to the study details page were detected; the differences appear limited to metadata and formatting, leaving core study information unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check93 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference2%

- Check100 days agoChange DetectedUpdated page to revision v3.1.0 and added a new academic citation (authors, title, journal, date, DOI) for a study on mirvetuximab soravtansine in FRα-high platinum-resistant ovarian cancer.SummaryDifference2%

Stay in the know with updates to Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.